Interferon alfa
As of the edition of 20 October 2026, Interferon alfa is a protein: marketed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Protein
- Brand name
- Egiferon
- Approvals on record
- 5 in 5 regions
- Holder of the most recent approval
- Labo'Life; 4 holders in all
- Registered trials
- 148, 20 stopped early
- Disease areas
- Cancer; Blood and lymph; Urinary and reproductive; Immune system; Pregnancy and women's health; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 3 | 1 | 1 |
| Phase 1 | 11 | 9 | 0 | 1 |
| Phase 2 | 92 | 65 | 1 | 16 |
| Phase 3 | 38 | 24 | 0 | 2 |
| Phase 4 | 2 | 1 | 0 | 0 |
| All trials | 148 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Dainippon Sumitomo Pharma | Originator |